The Influence of 150-Cavity Binders on the Dynamics of Influenza A Neuraminidases as Revealed by Molecular Dynamics Simulations and Combined Clustering

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Greenway, Kyle T ^a   LeGresley, Eric B ^a   Pinto, B Mario ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ALKENE; APOENZYME; HOLOENZYME; LIGAND; OSELTAMIVIR; SIALIDASE INHIBITOR; TRIAZOLE; VIRUS SIALIDASE; ZANAMIVIR;

150 CAVITY BINDER; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME BINDING; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; INFLUENZA VIRUS A; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS;

APOPROTEINS; BINDING SITES; CATALYTIC DOMAIN; CLUSTER ANALYSIS; ENZYME STABILITY; INFLUENZA A VIRUS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; NEURAMINIDASE; PROTEIN STRUCTURE, SECONDARY;

EID: 84875440351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059873     Document Type: Article

References (37)

1. Von Itzstein M, (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6: 967-974.
2. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nat 443: 45-49.
3. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, et al. (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17: 1266-1268.
4. Kar P, Knecht V, (2012) Mutation-Induced Loop Opening and Energetics for Binding of Tamiflu to Influenza N8 Neuraminidase. J Phys Chem B 116: 6137-6149.
5. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, et al. (2011) Cochrane Database Syst Rev Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children- a review of unpublished data. 2011: CD008965.
6. Rudrawar S, Dyason JC, Rameix-Welti M-A, Rose FJ, Kerry PS, et al. (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Comm 1: 113-119.
7. Mohan S, McAtamney S, Haselhorst T, Von Itzstein M, Pinto BM, (2010) Carbocycles Related to Oseltamivir as Influenza Virus Group-1-Specific Neuraminidase Inhibitors. Binding to N1 Enzymes in the Context of Virus-like Particles. J Med Chem 53: 7377-7391.
8. Ye D, Shin W-J, Li N, Tang W, Feng E, et al. (2012) Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. Eur J of Med Chem 54: 764-770.
9. Wen W-H, Wang S-Y, Tsai K-C, Cheng Y-SE, Yang A-S, et al. (2010) Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 18: 4074-4084.
10. Du J, Cross TA, Zhou HX, (2012) Recent progress in structure-based anti-influenza drug design. Drug Discov Today 17: 19-20.
11. Amaro RE, Swift RV, Votapka L, Li WW, Walker RC, et al. (2011) Mechanism of 150-cavity formation in influenza neuraminidase. Nat Comm 2: 388-395.
12. Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, et al. (2011) Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition. PLoS Pathog 7: e1002249.
13. Amaro RE, Minh DD, Cheng LS, Lindstrom WM Jr, Olson AJ, et al. (2007) Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 129: 7764-7765.
14. Rungrotmongkol T, Frecer V, De-Eknamkul W, Hannongbua S, Miertus S, (2009) Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res 82: 51-58.
15. García-Sosa AT, Sild S, Maran U, (2008) Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Mod 48: 2074-2080.
16. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, et al. (2008) Ensemble-Based Virtual Screening Reveals Potential Novel Antiviral Compounds for Avian Influenza Neuraminidase. J Med Chem 51: 3878-3894.
17. Li Y, Zhou B, Wang R, (2009) Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. J Mol Graphics Modell 28: 203-219.
18. Park JW, Jo WH, (2010) Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Euro J Med Chem 45: 536-541.
19. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, et al. (2006) An Epidemiologically Significant Epitope of a 1998 Human Influenza Virus Neuraminidase Forms a Highly Hydrated Interface in the NA-Antibody Complex. J Mol Biol 356: 651-663.
20. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nat 453: 1258-1261.
21. Udommaneethanakit T, Rungrotmongkol T, Bren U, Frecer V, Stanislav M, (2009) Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues. J Chem Inf Model 49: 2323-2332.
22. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, et al. (2009) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr, Sect D: Biol Crystallogr 66: 12-21.
23. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, et al. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 35: W522-W525.
24. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comp Chem 26: 1668-1688.
25. The PyMOL Molecular Graphics System. Version 1.5.0.1, Schrödinger, LLC.
26. Lawrenz M, Wereszczynski J, Amaro R, Walker R, Roitberg A, et al. (2010) Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy. Proteins: Structure, Function, and Bioinformatics 78: 2523-2532.
27. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, et al. (2009) Gaussian 09, Revision A.02.
28. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, et al. (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117: 5179-5197.
29. Dupradeau F-Y, Pigache A, Zaffran T, Savineau C, Lelong R, et al. (2010) The R.E.D. tools: advances in RESP and ESP charge derivation and force field library building. Phys Chem Chem Phys 12: 7821-7839.
30. Trott O, Olson AJ, (2009) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comp Chem 31: 455-461.
31. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comp Chem 25: 1157-1174.
32. Hess B, Kutzner C, Van der Spoel D, Lindahl E, (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput 4: 435-447.
33. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
34. Da Silva AWS, Vranken WF, (2012) ACPYPE-AnteChamber PYthon Parser interfacE. BMC Res Notes 5: 367-374.
35. Hoover WG, (1985) Canonical dynamics: Equilibrium phase-space distributions. Phys Rev A 31: 1695-1697.
36. Parrinello M, (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys 52: 7182-7190.
37. Daura X, Gademann K, Jaun B, Seebach D, Van Gunsteren WF, et al. (1999) Peptide Folding: When Simulation Meets Experiment. Angew Chem Int Ed 38: 236-240.